In the Journal of clinical oncology published online November 19, 2012 "(Journal of Clinical Oncology) magazine, published the results of a
In the Journal of clinical oncology published online November 19, 2012 "(Journal of Clinical Oncology) magazine, published the results of a study of the Ohio University John M. McLaughlin et al, the study for biopsy confirmed breast cancer diagnosis and treatment (Dx2Tx) began a long interval between the judgment on the rate of survival of patients.
The study was a noninterventional, were retrospectively analyzed, the patients were recruited to participate in the North Carolina health adult women, according to the North Carolina Cancer Registry - health insurance claims database, these women are diagnosed with breast cancer during the period of January 2000 December 31, 2002 1 log, follow-up data in the study by the end of July 31, 2006. Through the establishment of the Cox proportional hazards regression model of breast cancer diagnosis delay after the duration of treatment was more than 60 days of survival were evaluated.
The study cohort consisted of 1786 low-income adult women with a mean age of 61.6 years. A large proportion of patients (44.3%) were ethnic minorities. The mean interval between diagnosis and initiation of treatment was 22 days. Adjusted Cox proportional hazards regression model showed that, despite the impact of Dx2Tx on the early diagnosis of the patients was not the length, but for advanced patients, diagnosis and treatment of more than 60 days for the first time interval between the whole and the poor survival (hazard ratio [HR, 1.66; 95% CI, 1 to 2.77; P =.05) survival with breast cancer specific rate (HR, 1.85; 95% CI, 1.04 to 3.27; P =.04) have a significant association between.
According to the research results, in 10 cases of breast cancer are diagnosed in female patients, namely 1 patients waiting to start treatment time at least 60 days. And for patients with advanced stage, waiting to begin treatment longer than 60 days, there were 66% overall mortality increase the mortality of breast cancer specific risk and increased risk of 85%. Therefore, the researchers suggest, for those patients with advanced breast cancer, should be made to improve the acceptance of corresponding interventions for the treatment of timeliness, and clinicians should strive to promptly diagnosed with advanced breast cancer patients identified and start treatment.